Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Monday

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is projected to announce its Q1 2025 earnings results after the market closes on Monday, May 12th. Analysts expect Neumora Therapeutics to post earnings of ($0.40) per share for the quarter.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.09. On average, analysts expect Neumora Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neumora Therapeutics Stock Up 0.6 %

Shares of NMRA stock traded up $0.00 during mid-day trading on Friday, reaching $0.78. The stock had a trading volume of 878,672 shares, compared to its average volume of 1,485,867. Neumora Therapeutics has a one year low of $0.62 and a one year high of $17.19. The firm has a market cap of $125.55 million, a PE ratio of -0.42 and a beta of 2.89. The firm's 50 day simple moving average is $1.03 and its 200 day simple moving average is $5.38.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on NMRA shares. Guggenheim downgraded shares of Neumora Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday, March 7th. HC Wainwright lowered their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Bank of America reissued an "underperform" rating and issued a $1.00 price target (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Finally, Stifel Nicolaus downgraded Neumora Therapeutics from a "buy" rating to a "hold" rating and cut their target price for the stock from $6.00 to $2.00 in a research report on Friday, March 7th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $9.29.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.